Remarkable plasma HIV RNA decrease by ombitasvir/paritaprevir/ritonavir in an HIV-HCV coinfection case

被引：0
|
作者：
Yoshimura, Yukihiro [1 ]
Miyata, Nobuyuki [1 ]
Komatsu, Hirokazu [2 ]
Tachikawa, Natsuo [1 ]
机构：
[1] Yokohama Municipal Citizens Hosp, Dept Infect Dis, Yokohama, Kanagawa, Japan
[2] Yokohama Municipal Citizens Hosp, Dept Gastroenterol, Yokohama, Kanagawa, Japan
来源：
AIDS | 2018年 / 32卷 / 01期
关键词：
VIVO ANTIVIRAL ACTIVITY; RESISTANCE PROFILE; SHORT-TERM; IN-VITRO; INHIBITOR; PROTEASE; RITONAVIR;
D O I：
10.1097/QAD.0000000000001665
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：127 / 129
页数：3
相关论文
共 50 条
  • [1] DASABUVIR AND OMBITASVIR/PARITAPREVIR/RITONAVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HIV-HCV COINFECTION: REAL LIFE INTERIM ANALYSIS OF AN ITALIAN MULTICENTRE COMPASSIONATE USE PROGRAM
    Teti, E.
    Ricciardi, A.
    Antinori, A.
    Galli, M.
    Rizzardini, G.
    Di Biagio, A.
    Angarano, G.
    Bruno, R.
    Mussini, C.
    De Luca, A.
    Cattelan, A.
    Lazzarin, A.
    Taliani, G.
    Monforte, A. D'Arminio
    Mastroianni, C. M.
    Di Perri, G.
    Maggiolo, F.
    Puoti, M.
    Castelli, F.
    Gori, A.
    Boffa, N.
    Cacopardo, B.
    Giacometti, A.
    Parruti, G.
    Vullo, V.
    Chirianni, A.
    Pennica, A.
    Pasquazzi, C.
    Sighinolgi, L.
    Gentilotti, E.
    Sarmati, L.
    Andreoni, M.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S763 - S763
  • [2] Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients With HIV/HCV Coinfection: Results of an Italian Compassionate Use Program
    Andreoni, Massimo
    Teti, Elisabetta
    Antinori, Andrea
    Milazzoi, Laura
    Sollima, Savatore
    Rizzardini, Giuliano
    Di Biagio, Antonio
    Saracino, Annalisa
    Bruno, Raffaele
    Borghi, Vanni
    De Luca, Andrea
    Cattelan, Annamaria
    Hasson, Hamid
    Taliani, Gloria
    Monforte, Antonella D'Arminio
    Mastroianni, Claudio Maria
    Di Perri, Giovanni
    Bigoni, Sara
    Puoti, Massimo
    Spinetti, Angiola
    Gori, Andrea
    Boffa, Nicola
    Cacopardo, Bruno
    Giacometti, Andrea
    Parruti, Giustino
    Vullo, Vincenzo
    Chirianni, Antonio
    Pennica, Alfredo
    Pasquazzi, Caterina
    Segala, Daniela
    Sarmati, Loredana
    CLINICAL INFECTIOUS DISEASES, 2017, 64 (05) : 680 - 683
  • [3] Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis
    Jingjing Wu
    Peng Huang
    Haozhi Fan
    Ting Tian
    Xueshan Xia
    Zuqiang Fu
    Yan Wang
    Xiangyu Ye
    Ming Yue
    Yun Zhang
    Virology Journal, 16
  • [4] Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis
    Wu, Jingjing
    Huang, Peng
    Fan, Haozhi
    Tian, Ting
    Xia, Xueshan
    Fu, Zuqiang
    Wang, Yan
    Ye, Xiangyu
    Yue, Ming
    Zhang, Yun
    VIROLOGY JOURNAL, 2019, 16
  • [5] Pathogenesis of HIV-HCV coinfection
    Kim A.Y.
    Lauer G.M.
    Current Infectious Disease Reports, 2007, 9 (4) : 331 - 337
  • [6] Optimal management of HIV-HCV coinfection
    Pol S.
    Vallet-Pichard A.
    Current Hepatology Reports, 2014, 13 (4) : 295 - 303
  • [7] Increased plasma lipoperoxidation and protein oxidation in HIV-HCV coinfection
    Sob, JE
    Ngondi, JL
    Oben, J
    FREE RADICAL BIOLOGY AND MEDICINE, 2005, 39 : S130 - S130
  • [8] Suspected pharmacokinetic interaction between raltegravir and the 3D regimen of ombitasvir, dasabuvir and paritaprevir/ritonavir in an HIV-HCV liver transplant recipient
    Dario Cattaneo
    Salvatore Sollima
    Nitin Charbe
    Chiara Resnati
    Emilio Clementi
    Cristina Gervasoni
    European Journal of Clinical Pharmacology, 2016, 72 : 365 - 367
  • [9] Suspected pharmacokinetic interaction between raltegravir and the 3D regimen of ombitasvir, dasabuvir and paritaprevir/ritonavir in an HIV-HCV liver transplant recipient
    Cattaneo, Dario
    Sollima, Salvatore
    Charbe, Nitin
    Resnati, Chiara
    Clementi, Emilio
    Gervasoni, Cristina
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 72 (03) : 365 - 367
  • [10] Challenges for HCV vaccine development in HIV-HCV coinfection
    Lambotin, Melanie
    Barth, Heidi
    Moog, Christiane
    Habersetzer, Francois
    Baumert, Thomas F.
    Stoll-Keller, Francoise
    Fafi-Kremer, Samira
    EXPERT REVIEW OF VACCINES, 2012, 11 (07) : 791 - 804
12345